Fig. 6

Expression and clinical correlation of Twist1 in glioma patients. The expression of Twist1 in clinical glioma samples and its relationship with patients’ survival time were analyzed in different glioma datasets. A A high level of Twist1 was observed in gliomas compared with control tissues from the French glioma database (n = 284, p = 0.014). Student’s t-test was used for statistical analysis. B The expression of Twist1 was increased from the WHO tumor grade II to grade IV in the CGGA glioma database (n = 692, p = 1.22e-14). One-way ANOVA analysis was used for statistical analysis. C Twist1 expression was up-regulated in mesenchymal subtypes compared to other indicated subtypes of glioma tumors from the TCGA glioma database (n = 170, p = 4.62e-04). One-way ANOVA analysis was used for statistical analysis. D Twist1 was hyper-expressed in the recurrent gliomas compared to the primary gliomas from the CGGA glioma database (n = 693, p = 7.12e-09). Student’s t-test was used for statistical analysis. E Kaplan-Meier survival analysis of patients from TCGA glioma database (n = 504, p = 0.02, left panel) and CGGA glioma database (n = 668, p = 7.12e-09, right panel) stratified by Twist1 expression. A lower survival probability in high Twist1 expressed patients compared with those patients with low Twist1 expression was revealed. Median Twist1 expression was used for stratification into Twist1 high expression and Twist1 low expression tumors